Griseofulvin 165 MG Oral Tablet — RxCUI 245248
RxNorm drug concept · Semantic clinical drug
RxCUI 245248
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI245248
Official nameGriseofulvin 165 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Griseofulvin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It really can be — and that's one of the most important things to understand about this medication. Fungal infections of the nails especially can take at least 4 to 6 months to cle...
- How long do I have to take griseofulvin? It seems like a really long time.
- Yes, and specifically with a fatty meal if you can. Studies show that eating something high in fat — like a full meal with dairy or meat — dramatically increases how much of the me...
- It's best to avoid alcohol entirely during treatment. The combination of griseofulvin and alcohol has been reported to cause an unpleasant and potentially dangerous reaction — naus...
🕸️ Concept Web — How Griseofulvin 165 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Griseofulvin 165 MG Oral Tablet
RxCUI 245248 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Griseofulvin
5021IN
-
Griseofulvin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Fulvicin P/G
217214BN
-
Fulvicin P/G
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Griseofulvin Oral Tablet
372355SCDF -
Griseofulvin Oral Product
1158540SCDG -
Griseofulvin Pill
1158541SCDG -
Griseofulvin Oral Tablet [Fulvicin P/G]
369357SBDF -
Fulvicin P/G Oral Product
1173972SBDG -
Fulvicin P/G Pill
1173973SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Griseofulvin Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Griseofulvin 165 MG
328326SCDC -
Griseofulvin 165 MG Oral Tablet [Fulvicin P/G]
92758SBD -
Griseofulvin 165 MG [Fulvicin P/G]
562881SBDC
-
Griseofulvin 165 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Griseofulvin 165 MG
SCDC · 328326 -
Griseofulvin Oral Tablet
SCDF · 372355 -
Griseofulvin Oral Product
SCDG · 1158540 -
Griseofulvin Pill
SCDG · 1158541
Brand-Name Concepts
-
Griseofulvin 165 MG Oral Tablet [Fulvicin P/G]
SBD · 92758 -
Griseofulvin 165 MG [Fulvicin P/G]
SBDC · 562881 -
Griseofulvin Oral Tablet [Fulvicin P/G]
SBDF · 369357 -
Fulvicin P/G Oral Product
SBDG · 1173972 -
Fulvicin P/G Pill
SBDG · 1173973 -
Fulvicin P/G
BN · 217214
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 245248 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 62135-0501-30 | 30 TABLET in 1 BOTTLE (62135-501-30) | ULTRAMICROSIZE GRISEOFULVIN | Chartwell RX, LLC | 2025-01-30 |
| 73308-0435-30 | 30 TABLET in 1 BOTTLE (73308-435-30) | ULTRAMICROSIZE GRISEOFULVIN | Ayurax, LLC. | 2025-01-30 |
Observed labelers:
Ayurax, LLC. (1) ·
Chartwell RX, LLC (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.